Navigation Links
ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study
Date:9/15/2010

nerally well tolerated at all dose levels; there were no serious or severe adverse events, and no discontinuations from study drug due to adverse events.
  • All 27 volunteers (100 percent) who were given VP20621 had positive non-toxigenic C. difficile stool cultures by day 6, suggesting that VP20621 rapidly colonizes the susceptible GI tract.
  • No patient dosed with VP20621 tested positive for toxin-producing strains of C. difficile during the 28-day study period.
  • By comparison, 5 of 9 subjects (56 percent) who received placebo (i.e. did not receive VP20621) tested positive for either toxin-negative or toxin-positive C. difficile during the study period.

  • "I am highly encouraged by the data from this Phase 1 study of VP20621, which for the first time support the tolerability and colonization effectiveness of non-toxigenic C. difficile, mimicking what we have inferred from observing colonization of patients with these organisms," commented Dale Gerding, M.D., Associate Chief of Staff for Research at the Hines VA Hospital.  "Colonization protection of VP20621 awaits demonstration in a Phase 2 clinical trial in CDI patients to confirm pre-clinical data and observational studies of natural colonization in humans that have demonstrated high levels of protection against CDI that approach 100%."

    "Previous animal and clinical observational studies have described the prevention of symptomatic CDI by colonization of the large bowel with non-toxin producing strains of C. difficile," commented Dr. Colin Broom, ViroPharma's chief scientific officer.  "We now know that VP20621 appears to behave similarly, rapidly colonizing the large bowel and potentially protecting it from colonization with dangerous toxin-producing strains of C. difficile. We are excited by these positive data and expect to move rapidly into Phase 2 studies with VP20621 in the coming months
    '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. ViroPharma to Present at Three Upcoming Healthcare Conferences
    2. ViroPharma to Present at the Natixis Bleichroeder Conference
    3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
    4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
    5. ViroPharma Announces Discontinuation of HCV-796 Development
    6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
    7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
    8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
    9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
    10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
    11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/3/2015)... YORK , Aug. 3, 2015   ... global pharmaceutical company Allergan plc is ... Deloitte and Intermountain Healthcare to include ... harness ConvergeHEALTH,s OutcomesMiner analytics platform to generate real-world ... outcomes. "We look forward to expanding ...
    (Date:8/3/2015)... VWR (NASDAQ: VWR ), a leading, independent ... of its global website, www.vwr.com , to improve functionality ... site, guests will enjoy enhanced content on a modern and ... site now includes: , a simplified navigation; ... , the ability to search by discipline/industry. ...
    (Date:8/3/2015)... 3, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ... Second Quarter 2015 Investor Conference Call and webcast at 4:30 ... The call will cover an update on Merrimack,s progress ... financials. A press release detailing the information to be ... of Monday, August 10. Investors and the general public ...
    Breaking Medicine Technology:ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 3ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 4VWR's New Website Redesign Provides Improved Functionality for Customers 2Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2
    ... , ST. LOUIS , Feb. 1 ... The TODAY Show featured Dr. Mauricio Arruda ... Heart & Vascular Institute in Cleveland, Ohio , performing ... its broadcast this morning.  The patient was a 69 year ...
    ... DIEGO , Feb. 1 CareFusion (NYSE: ... today that it has entered into a 5-year sole source ... top ten Catholic health systems in the U.S., to upgrade ... further into the operating rooms and cath labs. , CareFusion,s ...
    Cached Medicine Technology:Stereotaxis System Procedure Featured on NBC's The TODAY Show 2CareFusion Announces 5-Year, Sole Source Pyxis(R) Perioperative Solutions Agreement With CHRISTUS Health 2CareFusion Announces 5-Year, Sole Source Pyxis(R) Perioperative Solutions Agreement With CHRISTUS Health 3CareFusion Announces 5-Year, Sole Source Pyxis(R) Perioperative Solutions Agreement With CHRISTUS Health 4
    (Date:8/3/2015)... FL (PRWEB) , ... August 03, 2015 , ... ... to date of its industry-defining contract lifecycle management solution, as well as announced ... designed to increase the speed and ease of contract management tasks as well ...
    (Date:8/3/2015)... , ... August 03, 2015 , ... ... the development of it’s new program “Designing Secure Healthcare Systems” This three-day, ... and technology leaders from healthcare organizations with access to the tactics, techniques and ...
    (Date:8/3/2015)... ... ... A July 13 article from The Daily Mail titled "Jab That ... Can Last 'For Five Weeks'" discusses the use of stem cells to help ... harvesting stem cell-rich bone marrow from the hip, known as bone marrow stromal cells ...
    (Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... insurance brokerage firm, announced today that Joe Williams has joined its growing California ... and delivering HUB's differentiated service model to his clients. Mr. Williams will be ...
    (Date:8/3/2015)... ... August 03, 2015 , ... ... management and investigative services, has introduced a new logo and comprehensive brand ... that improve business outcomes for its customers. EMSI’s new tagline, “Powerful Information. ...
    Breaking Medicine News(10 mins):Health News:Novatus Unveils Milestone Software Release 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2
    ... WASHINGTON, Oct. 8 The U.S. Department of,Labor ... 700,jobless workers with partial premium payments for health ... nearly 700 North Carolinians who are,looking for work ... afford health insurance for themselves and their families," ...
    ... YORK, Oct. 8 Weight Watchers,International, Inc. (NYSE: ... Steven,C. McCormick to serve as its President, North ... with extensive consumer product,operations and general management experience, ... its North American products,publishing and licensing businesses and ...
    ... their levels correlate with cardiovascular trouble , , WEDNESDAY, Oct. ... activity of genes in white blood cells might someday ... of chest pain, researchers report. , The finding is ... the first issue of a new American Heart Association ...
    ... Sinobiomed Inc.,("Sinobiomed", or "the Company") (OTC Bulletin ... of Directors voted on October 2, 2008 to ... Officer under a,Corporate Consulting Services Agreement to be ... Choong has been appointed to the Company,s audit,committee. ...
    ... (OTC Bulletin Board:,VYTC) today announced that effective October ... as an independent scientific consultant to Vyta Corp.,Dr. ... Development at,BIOAGRA, LLC, a joint venture, equally owned ... 15, 2008, Vyta Corp announced its filing of,foreclosure ...
    ... 8 Dr. Jane Hightower -- widely,acknowledged as the ... who regularly consume certain types of fish -- today,released ... inform and protect,the public from the risks of mercury ... Hightower has released a new book, Diagnosis:,Mercury: Money, Politics, ...
    Cached Medicine News:Health News:Weight Watchers Names Steven C. McCormick as President, North America 2Health News:Weight Watchers Names Steven C. McCormick as President, North America 3Health News:Blood Cell Genes May Signal Heart Disease 2Health News:Sinobiomed Directors Confirm Hiring of New Chief Financial Officer 2Health News:Vyta Corp Announces Engagement of Dr. Nino Sorgente as Independent Consultant 2Health News:New Evidence Highlights Dangers of Mercury Toxicity in Fish 2
    Inquire...
    Richardson Retractor...
    A full, rounded look that adds greater dimension to the breast. Moderate base, with a higher profile than our Style 1600 implant....
    ... implant is an expanded porous polytetrafluoroethylene,material ... repair of the soft tissues of ... in sheets and shaped geometries with ... implant strands are packaged with and,without ...
    Medicine Products: